Will resistance to lapatinib develop?

The resistance mechanisms of Lapatinib (Lapatinib) are diverse, and one of the common mechanisms is variation in the HER2 signaling pathway. In patients with HER2-positive breast cancer, HER2 gene mutations or amplifications may cause tumor cells to become resistant to lapatinib. Patients may develop drug resistance while taking lapatinib. Resistance is a phenomenon that occurs with almost all drugs, and the time when drug resistance occurs varies from person to person. There is no standard data for reference. When a patient develops drug resistance while taking lapatinib, he or she must not change the drug or increase the original dosage without permission. Instead, he or she needs to seek medical treatment promptly and follow the doctor's advice for follow-up treatment.